NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

The various time consuming contractor and sub-contractor snafus along the way*, means that (1) any evidence submission to NICE now brings ten year data from time of last randomization. (2) The conclusion of a NICE reimbursement review should be by April, at which time QALY reimbursement increases due to the new more supportive regulation.

The above two factors together increase the valuation. Even Ex thinks that if DCVax-l is approved, it could be reimbursed by about $100,000 (aka 75,000 UK Pounds) per patient, based on just five year data.

Now there is ten year data, which can increase valuation substantially (along with the aforementioned April QALY increase which Ex already considered in his above estimate).

NWBO, now owning the means of production, means that ultimately, with Flaskworks’ units eventually in full operation, profit margins could be 80%.

* There were many over the past decade.